Merck Sees Aggressive Bullish Options Activity as $2M in Call Premiums Target Upside Above $135
By TrendSpider Editor
Merck & Company, Inc. (MRK) is drawing significant attention in the options market today, with six unusual call contracts generating a combined $1,995,198 in total premium as shares trade at $128.925, up 0.87% on the session. The most striking contract of the day is a September 18 $145 call that
Merck Sees Aggressive Bullish Options Activity as $2M in Call Premiums Target Upside Above $135
Merck & Company, Inc. (MRK) is drawing significant attention in the options market today, with six unusual call contracts generating a combined $1,995,198 in total premium as shares trade at $128.925, up 0.87% on the session. The most striking contract of the day is a September 18 $145 call that printed 10,139 contracts against open interest of just 1,427, representing a staggering 711% of existing open interest and suggesting a large directional bet on a meaningful move higher. With MRK trading near the upper end of its 52-week range of $77.58 to $135.05, the positioning implies some traders are anticipating a breakout above prior highs in the weeks ahead.
Key Drivers of the MRK Stock Move
- Main Catalyst: Six unusual call contracts were flagged today totaling $1,995,198 in premium. The dominant contract was the September 18 $145 call with 10,139 contracts and 711% of open interest, followed by the September 18 $135 call with 1,937 contracts at $610,155 in premium and the March 19, 2027 $155 call with 1,000 contracts at $360,000 in premium.
- Bull Case: All six contracts are calls, representing a fully one-sided bullish posture with zero put contracts flagged. The September 18 $145 call alone generated $760,425 in premium across 10,139 contracts, while the $155 strike expiring March 2027 signals at least some participants are positioned for a sustained rally well above current levels over the next seven months.
- Bear Case: Every contract flagged is out of the money, and MRK at $128.925 is already pressing toward its 52-week high of $135.05. The $132 call expiring this Friday, August 7, with 919 contracts and 130% of open interest, is a short-dated bet that could expire worthless in a matter of days if the stock fails to extend its gains quickly.
The forward setup for MRK looks constructive on a technical basis, with the stock reclaiming territory near its 52-week high and options traders stacking bullish bets at multiple strike levels and expirations. The clustering of activity at the $135 and $145 strikes for September suggests that sophisticated market participants are not just speculating on a near-term pop but may be positioning for a catalyst that could drive shares through prior resistance. The presence of a longer-dated $155 strike for March 2027 adds a layer of conviction to the broader bullish thesis, pointing to expectations of continued momentum into early next year.
MRK Unusual Options Activity
- Call | Strike: $132 | Expiry: August 7, 2026 | Volume: 919 | Open Interest: 130% of OI (OTM)
- Call | Strike: $135 | Expiry: September 18, 2026 | Volume: 1,937 | Open Interest: 41% of OI (OTM)
- Call | Strike: $145 | Expiry: September 18, 2026 | Volume: 859 | Open Interest: 60% of OI (OTM)
- Call | Strike: $135 | Expiry: August 21, 2026 | Volume: 1,401 | Open Interest: 29% of OI (OTM)
- Call | Strike: $155 | Expiry: March 19, 2027 | Volume: 1,000 | Open Interest: 62% of OI (OTM)
- Call | Strike: $145 | Expiry: September 18, 2026 | Volume: 10,139 | Open Interest: 711% of OI (OTM)
MRK Seasonality
August and September historically represent an active period for pharmaceutical stocks as companies navigate mid-year pipeline updates and conference season, which can serve as catalysts for sharp directional moves. The clustering of September expiration calls today aligns with a window in which major drug companies often present clinical data or guidance updates that can move shares materially.
MRK Relative Performance
MRK is up 0.87% on the session and trading at $128.925, positioning it near the top of its 52-week range between $77.58 and $135.05. The stock has recovered substantially from its 52-week low, reflecting renewed investor interest in large-cap pharma, and today's price action combined with aggressive call buying suggests MRK is outperforming on a relative basis compared to where it spent much of the past year.
More on MRK
- Merck Stock Hovers Near 52-Week High of $132.53 as Shares Hold Steady
- Merck Stock Inches Toward 52-Week High as Shares Consolidate at $131.10
- Merck Edges Toward 52-Week High as Shares Climb to $131.10
- Merck Surges 2.33% to $130.49, Pushing Toward a 52-Week High
- Merck Stock Climbs Within Striking Distance of Its 52-Week High as Momentum Builds
Latest Market News
- Visa Stock Inches Toward 52-Week High as Shares Climb 0.98% in Monday's Session
- Walmart Sees $1.7M in Unusual Options Activity Led by Bullish January 2027 Call Sweep
- Broadcom Surges 6.76% as AVGO Breaks Out Toward 52-Week High
- AMD Surges 8.57% in a Single Session, Pushing Shares Back Toward 52-Week Highs
- Nike Stock Slides to $41.71, Pressing Against 52-Week Lows Amid Continued Pressure
- RTX Corporation Hovers Near 52-Week High as Shares Continue Steady Climb